AMERICAN SOCIETY OF CLINICAL ONCOLOGY(ASCO)

ASCO21 Virtual Scientific Program

June 4-8, 2021eCompendium

Copies of files obtained through links contained in this compendium are for personal use only and may not be reproduced without permission from ASCO® and the author of the presentation. This compilation of QR codes is intended as an educational resource and is for the exchange of scientific data to clinical investigators and health care professionals.

Copyright © 2021 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved.

PEMBROLIZUMAB

RCC

BELZUTIFAN(MK-6482)

Colorectal

PEMBROLIZUMAB + LENVATINIB

Gastric Melanoma RCC

Lung

PEMBROLIZUMAB + OLAPARIB

FAVEZELIMAB(MK-4280)

Colorectal

Gynecologic Hepatobiliary Translational

Hepatobiliary

LENVATINIB

Melanoma Lung Bladder RCC

Prostate Gynecologic Head and Neck GI/Gastric

Colorectal Hepatobiliary Across Tumor Types

Breast

TUCATINIB

Solid Tumor

Neurofibromatosis

SELUMETINIBOLAPARIB

Ovarian

Prostate

3

Melanoma

Title/Author

Presentation

Type

Date and Time

EDT

Download

Presentation

Download

Poster Slides

Crossover and rechallenge with pembrolizumab in recurrent patients from the

EORTC 1325-mg/KEYNOTE-054 phase 3 trial, pembrolizumab vs placebo after

complete resection of high-risk stage III melanoma

Eggermont AMM, Meshcheryakov A, Atkinson V, Blank CU, Mandala M, Long GV,

Barrow C, Di Giacomo AM, Fisher R, Sandhu S, Kudchadkar R, Ortiz Romero PL, Svane IM,

van Akkooi A, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suciu S, Robert C

Oral

Presentation

Sunday

June 6, 2021

8:00-11:00 AM ▼

KEYNOTE-555 Cohort B: Efficacy, safety, and pharmacokinetics of pembrolizumab

400 mg every 6 weeks as first-line therapy for advanced melanoma

Jacobs C, Rapoport B, Chan SW, Ruff P, Arance Fernandez A, Eizmendi KM, Anderson JR,

Lala M, Jain L, Akala O, Chartash E, Cohen G

Poster

Friday

June 4, 2021

9:00 AM ▼ ▼

PEMBROLIZUMAB

4

Lung

Title/Author

Presentation

Type

Date and Time

EDT

Download

Presentation

Download

Poster Slides

KEYNOTE-799: Phase 2 trial of pembrolizumab plus platinum chemotherapy and

radiotherapy for unresectable, locally advanced, stage III NSCLC

Jabbour SK, Lee KH, Frost N, Breder V, Kowalski DM, Alawin I, Levchenko E, Reguart N,

Martinez-Marti A, Houghton B, Paoli J-B, Safina S, Park K, Komiya T, Sanford A, Boolell V,

Liu H, Samkari A, Keller SM, Reck M

Poster

Discussion

Friday

June 4, 2021

8:00-11:00 AM ▼ ▼Health-related quality of life for pembrolizumab + ipilimumab vs pembrolizumab +

placebo in patients with metastatic NSCLC with PD-L1 tumor proportion score ≥50%:

KEYNOTE-598

Şendur MAN, Reck M, Rodríguez-Abreu D, Park K, Lee DH, Cicin I, Yumuk PF, Orlandi FJ,

Leal TA, Molinier O, Soparattanapaisarn N, Langleben A, Califano R, Medgyasszay B,

Hsia T-C, Otterson G, Xu L, Burke T, Samkari A, Boyer M

Poster

Friday

June 4, 2021

9:00 AM ▼ ▼

PEMBROLIZUMAB

5

Bladder

Title/Author

Presentation

Type

Date and Time

EDT

Download

Presentation

Download

Poster Slides

First-line pembrolizumab in cisplatin-ineligible patients with advanced urothelial

cancer: Response and survival results up to 5 years from the KEYNOTE-052

phase 2 study

O’Donnell PH, Balar AV, Vuky J, Castellano DE, Bellmunt J, Powles T, Bajorin DF, Grivas P,

Hahn NM, Plimack ER, Xu JZ, Godwin JL, Homet Moreno B, de Wit R

Oral

Presentation

Monday

June 7, 2021

8:00-11:00 AM ▼Pembrolizumab vs investigator’s choice of paclitaxel, docetaxel, or vinflunine

in recurrent, advanced urothelial cancer: 5-year follow-up from the phase 3

KEYNOTE-045 trial

Bellmunt J, Necchi N, de Wit R, Lee J-L, Fong L, Vogelzang NJ, Climent MA, Petrylak DP,

Choueiri TK, Gerritsen WR, Gurney H, Quinn DI, Culine S, Sternberg CN, Xu J,

Homet Moreno B, Godwin JL, Bajorin DF, Vaughn DJ, Fradet Y

Poster

Friday

June 4, 2021

9:00 AM ▼ ▼KEYNOTE-B15/EV-304: A phase 3, randomized, open-label study of perioperative

enfortumab vedotin plus pembrolizumab vs chemotherapy in cisplatin-eligible patients

with muscle-invasive bladder cancer

Hoimes C, Bedke J, Loriot Y, Nishiyama H, Fang X, Kataria RS, Homet Moreno B,

Galsky MD

Poster

Friday

June 4, 2021

9:00 AM ▼ ▼

PEMBROLIZUMAB

6

RCC

Title/Author

Presentation

Type

Date and Time

EDT

Download

Presentation

Download

Poster Slides

Pembrolizumab plus axitinib vs sunitinib as first-line therapy for advanced clear cell

renal cell carcinoma: Results from 42-month follow-up of KEYNOTE-426

Rini BI, Plimack ER, Stus V, Waddell T, Gafanov R, Pouliot F, Nosov D, Melichar B,

Soulières D, Borchiellini D, Vynnychenko I, McDermott RS, Azevedo SJ, Tamada S,

Kryzhanivska A, Li C, Burgents JE, Molife LR, Bedke J, Powles T

Oral

Presentation

Monday

June 7, 2021

8:00-11:00 AM ▼A phase 1b/2 umbrella study of investigational immune and targeted combination

therapies as first-line therapy for patients with advanced renal cell carcinoma

(Substudy03A)

Plimack ER, Hammers HJ, Choueiri TK, Rini BI, Motzer RJ, Suttner L, Perini RF,

Willemann-Rogerio J, Albiges L

Poster

Friday

June 4, 2021

9:00 AM ▼ ▼

PEMBROLIZUMAB

7

RCC

Title/Author

Presentation

Type

Date and Time

EDT

Download

Presentation

Download

Poster Slides

Pembrolizumab vs placebo as post-nephrectomy adjuvant therapy for patients with

renal cell carcinoma: Randomized, double-blind, phase 3 KEYNOTE-564 study

Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang Y-H, Hajek J,

Symeonides S, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas N,

Sawrycki P, Perini RF, Zhang P, Willemann-Rogerio J, Imai K, Quinn D, Powles T, on

behalf of the KEYNOTE-564 investigators

Plenary

Session

Sunday

June 6, 2021

1:00 PM ▼Disease-free survival as a predictor of overall survival in localized renal cell carcinoma

(RCC) following initial nephrectomy

Haas NB, Song Y, Willemann Rogerio J, Zhang S, Adejoro O, Carley C, Zhu J,

Bhattacharya R, Signorovitch J, Sundaram M

Poster

Friday

June 4, 2021

9:00 AM ▼ ▼

PEMBROLIZUMAB

8

Prostate

Title/Author

Presentation

Type

Date and Time

EDT

Download

Presentation

Download

Poster Slides

Pembrolizumab plus enzalutamide for enzalutamide-resistant, metastatic

castration-resistant prostate cancer: Updated analyses after one additional

year of follow-up from cohorts 4 and 5 of the KEYNOTE-199 study

Graff JN, Tagawa ST, Hoimes CJ, Gerritsen WR, Vaishampayan UN, Elliott T,

Hwang C, Ten Tije AJ, Omlin A, McDermott RS, Fradet Y, Kilari D, Ferrario C,

Uemura H, Niu C, Poehlein CH, de Wit R, Schloss C, de Bono JS, Antonarakis ES

Poster

Friday

June 4, 2021

9:00 AM ▼ ▼

PEMBROLIZUMAB

9

Gynecologic

Title/Author

Presentation

Type

Date and Time

EDT

Download

Presentation

Download

Poster Slides

ENGOT-en11/GOG-3053/KEYNOTE-B21: Phase 3 study of pembrolizumab or placebo

in combination with adjuvant chemotherapy with/without radiotherapy in patients

with newly diagnosed high-risk endometrial cancer

Van Gorp T, Mirza MR, Lortholary A, Cibula D, Walther A, Savarese A,

Barretina-Ginesta M-P, Ortaç F, Papadimitriou C, Bodnar L, Lai C-H, Korach J, Marth C,

Hasegawa K, Xie X, Barber EL, Coleman RL, Keefe S, Orlowski R, Slomovitz B

Poster

Friday

June 4, 2021

9:00 AM ▼ ▼

PEMBROLIZUMAB

10

Head and Neck

Title/Author

Presentation

Type

Date and Time

EDT

Download

Presentation

Download

Poster Slides

KEYNOTE-629: Health-related quality of life with pembrolizumab in patients with

locally advanced or recurrent or metastatic cutaneous squamous cell carcinoma

Bratland Å, Munoz-Couselo E, Mortier L, Roshdy O, González R, Schachter J, Arance AM,

Grange F, Meyer N, Joshi AJ, Billan S, Hughes BGM, Grob JJ, Ramakrishnan K, Zhang P,

Gumuscu B, Swaby RF, Gutzmer R

Poster

Friday

June 4, 2021

9:00 AM ▼ ▼

PEMBROLIZUMAB

11

GI/Gastric

Title/Author

Presentation

Type

Date and Time

EDT

Download

Presentation

Download

Poster Slides

First-line pembrolizumab plus chemotherapy vs chemotherapy in patients with

advanced esophageal cancer: Chinese subgroup analysis of KEYNOTE-590

Li Z, Sun Y, Ye F, Ma D, Yin X, Zhuang W, Yuan X, Qin S, Zhang Y, Gu K, Zhao K, Xiao J,

Cheng Y, Bai Y, Luo S, Wang L, Wang C, Cui Y, Mei L, Shen L

Poster

Friday

June 4, 2021

9:00 AM ▼ ▼Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic

gastric or gastroesophageal junction cancer: Initial findings of the global phase 3

KEYNOTE-811 study

Janjigian YY, Kawazoe A, Yañez P, Luo S, Lonardi S, Kolesnik O, Barajas O, Bai Y,

Shen L, Tang Y, Wyrwicz LS, Shitara K, Qin S, Van Cutsem E, Tabernero J, Li L,

Shih C-S, Bhagia P, Chung HC, on behalf of the KEYNOTE-811 investigators

Poster

Discussion

Friday

June 4, 2021

9:00-10:00 AM ▼

PEMBROLIZUMAB

12

Colorectal

Title/Author

Presentation

Type

Date and Time

EDT

Download

Presentation

Download

Poster Slides

Final overall survival for the phase 3 KN177 study: Pembrolizumab vs chemotherapy in

microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic

colorectal cancer (mCRC)

André T, Shiu K-K, Kim TW, Jensen BV, Jensen LH, Punt C, Smith D, Garcia-Carbonero R,

Alcaide-Garcia J, Gibbs P, de la Fouchardiere C, Rivera F, Elez E, Bendell J, Le DT,

Yoshino T, Zhong W, Fogelman D, Marinello P, Diaz Jr LA

Oral

Presentation

Monday

June 7, 2021

1:15-4:15 PM ▼

PEMBROLIZUMAB

13

Hepatobiliary

Title/Author

Presentation

Type

Date and Time

EDT

Download

Presentation

Download

Poster Slides

Pembrolizumab monotherapy for previously untreated advanced hepatocellular

carcinoma: Phase 2 KEYNOTE-224 study

Van Laethem JL, Borbath I, Karwal M, Verslype C, Van Vlierberghe H, Kardosh A,

Zagonel V, Stal P, Sarker D, Palmer D, Vogel A, Edeline J, Cattan S, Kudo M, Cheng AL,

Ogasawara S, Siegel AB, Chisamore M, Wang A, Zhu AX

Poster

Friday

June 4, 2021

9:00 AM ▼Pembrolizumab (pembro) vs placebo (pbo) in patients (pts) with advanced

hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from

the randomized, phase 3 KEYNOTE-240 study

Finn RS, Edeline J, Bouattour M, Cheng AL, Chan SL, Yau T, Garrido M, Knox J, Daniele B,

Zhu AX, Breder V, Lim HY, Ogasawara S, Siegel AB, Rahman A, Wei Z, Merle P

Poster

Friday

June 4, 2021

9:00 AM ▼

PEMBROLIZUMAB

14

Across Tumor Types

Title/Author

Presentation

Type

Date and Time

EDT

Download

Presentation

Download

Poster Slides

Pembrolizumab in microsatellite instability high/mismatch repair–deficient cancers:

Updated analysis from phase 2 KEYNOTE-158 study

Maio M, Ascierto PA, Manzyuk L, Motola-Kuba D, Penel N, Cassier PA,

Mendonca Bariani G, De Jesus Acosta A, Doi T, Longo Muñoz F, Miller Jr WH,

Oh D-Y, Gottfried M, Wang R, Jin F, Norwood K, Marabelle A

Poster

Friday

June 4, 2021

9:00 AM ▼A comprehensive literature review and meta-analysis on prevalence of BRCAm,

HRRm, and HRD+ across tumor types

Shao C, Wan J, Tang H, Marley A, Miller C, Brown M, Song Y, Han J, Adeboyege G

Poster

Friday

June 4, 2021

9:00 AM ▼A comprehensive literature review and meta-analysis on prognostic value of BRCAm,

HRRm, and HRD+ across tumor types

Shao C, Marley A, Tang H, Wan J, Miller C, Brown M, Song Y, Han J, Adeboyeje G

Poster

Friday

June 4, 2021

9:00 AM ▼Pembrolizumab patient-reported benefits: A perspective based on multiple tumors

Wu E, Miskala PH, Siddiqui MK, Rai P, Hajdukova E, Erpelding N, Vanderpuye-Orgle J Poster

Friday

June 4, 2021

9:00 AM ▼

PEMBROLIZUMAB

15

CRC

Title/Author

Presentation

Type

Date and Time

EDT

Download

Presentation

Download

Poster Slides

LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients

with previously treated selected solid tumors: Results from the colorectal cancer cohort

Gomez-Roca C, Yanez E, Im S-A, Castanon E, Senellart H, Doherty M, Garcia Corbacho J,

Lopez J, Basu B, Maurice-Dror C, Gill S, Ghori R, Kubiak P, Jin F, Norwood K, Chung HC

Poster

Friday

June 4, 2021

9:00 AM ▼

PEMBROLIZUMAB + LENVATINIB

16

Colorectal

Title/Author

Presentation

Type

Date and Time

EDT

Download

Presentation

Download

Poster Slides

LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in

patients with previously treated selected solid tumors: Results from the gastric

cancer cohort

Chung HC, Lwin Z, Gomez-Roca C, Longo Muñoz F, Yanez E, Castanon E, Graham DM,

Doherty M, Cassier P, Lopez J, Basu B, Hendifar AE, Maurice-Dror C, Gill S, Ghori R,

Kubiak P, Jin F, Norwood K, Saada-Bouzid E

Poster

Friday

June 4, 2021

9:00 AM ▼

PEMBROLIZUMAB + LENVATINIB

17

Hepatobiliary

Title/Author

Presentation

Type

Date and Time

EDT

Download

Presentation

Download

Poster Slides

Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers

in the multicohort phase 2 LEAP-005 study

Villanueva L, Lwin Z, Chung HC, Gomez-Roca C, Longo Muñoz F, Yanez E, Senellart H,

Doherty M, Garcia-Corbacho J, Hendifar AE, Maurice-Dror C, Gill S, Kim TW, Heudobler D,

Penel N, Ghori R, Kubiak P, Jin F, Norwood K, Graham DM

Poster

Friday

June 4, 2021

9:00 AM ▼

PEMBROLIZUMAB + LENVATINIB

18

Melanoma

Title/Author

Presentation

Type

Date and Time

EDT

Download

Presentation

Download

Poster Slides

Lenvatinib plus pembrolizumab for patients with advanced melanoma and confirmed

progression on a PD-1 or PD-L1 inhibitor: Updated findings of LEAP-004

Arance A, de la Cruz Merino L, Petrella TM, Jamal R, Ny L, Carneiro A, Berrocal A,

Marquez-Rodas I, Spreafico A, Atkinson V, Costa Svedman F, Mant A, Smith AD, Chen K,

Diede SJ, Krepler C, Long GV

Oral

Presentation

Sunday

June 6, 2021

8:00-11:00 AM ▼

PEMBROLIZUMAB + LENVATINIB

19

RCC

Title/Author

Presentation

Type

Date and Time

EDT

Download

Presentation

Download

Poster Slides

Health‐related quality‐of‐life analysis from the phase 3 CLEAR trial of lenvatinib plus

pembrolizumab or everolimus vs sunitinib for patients with advanced renal cell

carcinoma

Motzer R, Porta C, Alekseev B, Young Rha S, Choueiri T, Mendez-Vidal MJ, Hong S-H,

Kapoor A, Goh JC, Eto M, Wang J, Pan J, Asfaw AA, He CS, Mody K, Cella D

Oral

Presentation

Monday

June 7, 2021

8:00-11:00 AM ▼KEYNOTE-B61: Open-label phase 2 study of pembrolizumab in combination with

lenvatinib as first-line treatment for non–clear cell renal carcinoma

Lee C-H, Li C, Perini RF, Hoehn D, Albiges L

Poster

Friday

June 4, 2021

9:00 AM ▼ ▼

PEMBROLIZUMAB + LENVATINIB

20

RCC

Title/Author

Presentation

Type

Date and Time

EDT

Download

Presentation

Download

Poster Slides

Analysis of the CLEAR study in patients with advanced renal cell carcinoma: depth of

response and efficacy for selected subgroups in the lenvatinib-plus-pembrolizumab and

sunitinib treatment arms

Grunwald V, Powles T, Kopyltsov E, Kozlov V, Alonso Gordoa TA, Eto M, Hutson T,

Motzer R, Winquist E, Maroto P, Keam B, Procopio G, Wong S, Melichar B, Rolland F,

Oya M, Rodriguez-Lopez K, Saito K, Smith A, Porta C

Poster

Friday

June 4, 2021

9:00 AM ▼Post hoc analysis of the CLEAR study in advanced renal cell carcinoma: effect of

subsequent therapy on survival outcomes in the lenvatinib + everolimus versus

sunitinib treatment arms

Hutson T, Choueiri TK, Motzer R, Young Rha S, Alyasova A, Merchan J, Gurney H, Peer A,

Takagi T, Porta C, Powles T, Grunwald V, De Giorgi U, Vaishampayan U, Schmidinger M,

Glen H, Rodriguez-Lopez K, Xing D, Dutta L, Eto M

Poster

Friday

June 4, 2021

9:00 AM ▼

PEMBROLIZUMAB + LENVATINIB

21

Gynecologic

Title/Author

Presentation

Type

Date and Time

EDT

Download

Presentation

Download

Poster Slides

Health-related quality of life in advanced endometrial cancer patients treated with

lenvatinib + pembrolizumab or treatment of physician’s choice

Lorusso D, Colombo N, Casado Herraez A, Santin A, Colomba E, Miller DS,

Fujiwara K, Pignata S, Baron-Hay SE, Ray-Coquard IL, Shapira-Frommer R, Man Kim Y,

McCormack M, Bird S, Prabhu VS, Nguyen AM, Zhao Q, Dutta L, Makker V

Poster

Friday

June 4, 2021

9:00 AM ▼ ▼Treatment patterns and outcomes among patients with microsatellite stable (MSS)

advanced endometrial cancer who progressed following previous systemic therapy in

the United States: Endometrial cancer health outcomes (ECHO) retrospective chart

review study

Corman S, Kelkar SS, Odak S, Zhang J, Prabhu VS, Rusibamayila N, Macahilig C, Duska L

Poster

Friday

June 4, 2021

9:00 AM ▼

PEMBROLIZUMAB + LENVATINIB

22

Translational

Title/Author

Presentation

Type

Date and Time

EDT

Download

Presentation

Download

Poster Slides

Exploratory circulating biomarker analyses: Lenvatinib + pembrolizumab (L + P) in a

phase 1b trial in unresectable hepatocellular carcinoma (uHCC)

Zhu AX, Llovet JM, Kobayashi M, Ikeda M, Pracht M, Sung MW, Baron AD, Kudo M,

Meyer T, Okusaka T, Kumada H, Kaneko S, Hoshi T, Saito K, Li SD, Funahashi Y,

Minoshima Y, Dubrovsky L, Finn RS

Poster

Friday

June 4, 2021

9:00 AM ▼ ▼

PEMBROLIZUMAB + LENVATINIB

23

RCC

Title/Author

Presentation

Type

Date and Time

EDT

Download

Presentation

Download

Poster Slides

Phase 2 study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α inhibitor,

for Von Hippel-Lindau disease–associated clear cell renal cell carcinoma

Srinivasan R, Donskov F, Iliopoulos O, Rathmell WK, Narayan V, Maughan BL, Oudard S,

Else T, Maranchie JK, Welsh SJ, Roy A, Liu Y, Perini RF, Linehan WM, Jonasch E

Poster

Friday

June 4, 2021

9:00 AM ▼ ▼

BELZUTIFAN (MK-6482)

24

Lung

Title/Author

Presentation

Type

Date and Time

EDT

Download

Presentation

Download

Poster Slides

Phase 3 study of pembrolizumab with concurrent chemoradiation therapy followed

by pembrolizumab with or without olaparib vs concurrent chemoradiation therapy

followed by durvalumab in unresectable, locally advanced, stage III non-small-cell

lung cancer: KEYLYNK-012

Jabbour SK, Cho BC, Bria E, Kato T, Bhosle J, Gainor JF, Reguart N, Wang L,

Morgensztern D, Gurary EB, Ashraf TB, Lara-Guerra H, Reck M

Poster

Friday

June 4, 2021

9:00 AM ▼KEYLYNK-013: A phase 3 study of pembrolizumab in combination with concurrent

chemoradiation therapy followed by pembrolizumab with or without olaparib vs

concurrent chemoradiation therapy in patients with newly diagnosed limited-

stage SCLC

Rimner A, Lai V, Califano R, Jabbour SK, Faivre-Finn C, Cho BC, Kato T, Yu J, Yu L,

Zhao B, Pietanza MC, Byers L

Poster

Friday

June 4, 2021

9:00 AM ▼

PEMBROLIZUMAB + OLAPARIB

25

Colorectal

Title/Author

Presentation

Type

Date and Time

EDT

Download

Presentation

Download

Poster Slides

A phase 1 first-in-human study of the anti-LAG-3 antibody MK-4280 (favezelimab)

plus pembrolizumab in previously treated, advanced microsatellite stable

colorectal cancer

Garralda E, Sukari A, Lakhani NJ, Patnaik A, Lou Y, Im S-A, Golan T, Geva R, Wermke M,

de Miguel M, Palcza J, Jha S, Chaney M, Healy J, Falchook GS

Poster

Friday

June 4, 2021

9:00 AM ▼ ▼

FAVEZELIMAB (MK-4280)

26

Hepatobiliary

Title/Author

Presentation

Type

Date and Time

EDT

Download

Presentation

Download

Poster Slides

The cost effectiveness of first line lenvatinib versus atezolizumab and bevacizumab or

sorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in Canada

Trueman D, Liu Y, Geadah M, Hon N, Sabapathy S, Kamboj L, Li H, Lucero M, Meier G

Poster

Friday

June 4, 2021

9:00 AM ▼ ▼

LENVATINIB

27

Prostate

Title/Author

Presentation

Type

Date and Time

EDT

Download

Presentation

Download

Poster Slides

Indirect treatment comparison of the efficacy of olaparib 300 mg tablets BID and

cabazitaxel 25 mg/m2 every 3 weeks plus daily prednisolone and granulocyte

colony-stimulating factor in the treatment of patients with metastatic

castration-resistant prostate cancer

Reason T, McCrea C, Hettle R, Ghate S, Poehlein C, Olmos D

Poster

Friday

June 4, 2021

9:00 AM ▼

OLAPARIB

28

Ovarian

Title/Author

Presentation

Type

Date and Time

EDT

Download

Presentation

Download

Poster Slides

EFFORT: Efficacy of adavosertib in PARP resistance: A randomized 2-arm

non-comparative phase II study of adavosertib with or without olaparib in women

with PARP-resistant ovarian cancer

Westin SN, Coleman RL, Fellman B, Yuan Y, Sood A, Soliman P, Wright A, Horowitz N,

Campos S, Konstantinopoulos P, Levenback C, Gershenson D, Lu K, Bayer V, Tukdi S,

Rabbit A, Ottesen L, Godin R, Mills G, Li JF

Oral

Presentation

Monday

June 7, 2021

8:00-11:00 AM ▼Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated

(non-gBRCAm) platinum-sensitive relapsed ovarian cancer patients: Phase IIIb

OPINION primary analysis

Poveda A, Lheureux S, Colombo N, Cibula D, Lindemann K, Weberpals J, Bjurberg M,

Oaknin A, Sikorska M, González-Martín A, Madry R, Rubio Pérez M, Ledermann J,

Davidson R, Blakeley C, Bennett J, Brown J, Škof E

Poster

Friday

June 4, 2021

9:00 AM ▼Olaparib treatment in patients with platinum-sensitive relapsed ovarian cancer by

BRCA mutation and homologous recombination deficiency status: Overall survival

results from the phase II LIGHT study

Mathews C, Simpkins F, Cadoo K, Liu Y, Provencher D, McCormick C, EINaggar AC,

Altman AD, Gilbert L, Black D, Kabil N, Bennett J, Munley J, Yu H, Aghajanian C

Poster

Discussion

Friday

June 4, 2021

9:00 AM ▼

OLAPARIB

29

Breast

Title/Author

Presentation

Type

Date and Time

EDT

Download

Presentation

Download

Poster Slides

HER2CLIMB-04: Phase 2 open label trial of tucatinib + trastuzumab deruxtecan in

patients with HER2+ unresectable locally advanced or metastatic breast cancer with

and without brain metastases (trial in progress)

Krop I, Ramos J, Zhang C, Hamilton E

Poster

Friday

June 4, 2021

9:00 AM ▼ ▼Alliance A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + tucatinib/placebo in

patients with residual HER2-positive invasive breast cancer

O'Sullivan CC, Ballman KV, McCall L, Zemla T, Weiss A, Mitchell M, Blinder V, Tung NM,

Irvin MJ, Lee M, Goetz MP, Symmans WF, Borges VF, Krop I, Partridge AH, Carey LA

Poster

Friday

June 4, 2021

9:00 AM ▼

TUCATINIB

30

Breast

Title/Author

Presentation

Type

Date and Time

EDT

Download

Presentation

Download

Poster Slides

Updated results of tucatinib vs placebo added to trastuzumab and capecitabine for

patients with pretreated HER2+metastatic breast cancer with and without brain

metastases (HER2CLIMB)

Curigliano G, Mueller V, Borges V, Hamilton E, Hurvitz S, Loi S, Murthy R, Okines A,

Paplomata E, Cameron D, Carey L, Gelmon K, Hortobagyi G, Krop I, Loibl S, Pegram M,

Slamon D, Ramos J, Zhang C, Winer E

Poster

Friday

June 4, 2021

9:00 AM ▼ ▼Pharmacokinetic (PK) analyses in CSF and plasma from TBCRC049, an ongoing trial to

assess the safety and efficacy of the combination of tucatinib, trastuzumab, and

capecitabine for the treatment of leptomeningeal metastasis (LM) in HER2 positive

breast cancer

Stringer-Reasor EM, O'Brien BJ, Topletz-Erickson A, White J, Lobbous M, Riley K,

Childress J, Lamaster K, Melisko M, Morikawa A, de Groot JF, Krop I, Valero V, Rimawi M,

Wolff A, Tripathy D, Lin NU, Murthy RK

Poster

Friday

June 4, 2021

9:00 AM ▼

TUCATINIB

31

Solid Tumor

Title/Author

Presentation

Type

Date and Time

EDT

Download

Presentation

Download

Poster Slides

SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated

solid tumors with HER2 alterations (trial in progress)

Stinchcombe T, Monk BJ, Okines AFC, Pohlmann PR, Yu EY, Bekaii-Saab TS, Nakamura Y,

O'Malley DM, Kang V, Walker LN, Reck M

Poster

Friday

June 4, 2021

9:00 AM ▼ ▼

TUCATINIB

32

Neurofibromatosis

Title/Author

Presentation

Type

Date and Time

EDT

Download

Presentation

Download

Poster Slides

Health-related quality of life (HRQoL) among pediatric patients with neurofibromatosis

type 1 (NF1) and plexiform neurofibroma (PN) in the United States (US)

Yang X, Yoo HK, Amin S, Cheng WY, Sipsma H, Sundaresan S, Zhang L, Duh MS

Poster

Friday

June 4, 2021

9:00 AM ▼

SELUMETINIB